|
| At present, there are no synthetic microparticles or blood cells that have emerged as clinically relevant. There is an endless need, but short supply of blood and blood products for treating patients with bleeding disorders, trauma, internal bleeding, etc. In addition, there is no product that can be universally applied to treat bleeding disorders regardless of the cause: accidental or therapeutic (e.g., as in cancer therapy) exposure to cytotoxins, inherited clotting disorders (such as Haemophilia and von Willebrand's disease) or the prevention of bleeding in surgery or trauma. Finally, exogenous blood sources can be contaminated and be dangerous.
|
|
| |
|
| Microparticles made from a patient's own blood and infused back to the patient in the management of bleeding will avoid serious infections such as viral hepatitis associated with blood transfusions, and prevent allergic reactions and alloimmunization developed with blood transfusion or blood products presently used. Alternatively, this invention may be useful in the production of "universal" microparticles from universal donors (O negative donors: Rh negative). These "universal" MP could then be administered to any patient, regardless of blood type, to induce procoagulant activity.
|
|
| |
|
| At present, no synthetic microparticles or blood cells have emerged as being clinically useful. In addition, since the patient's own blood can be used, the risk of acquiring infectious agents from an external blood supply is decreased substantially. |
|
| |
|
| Microparticles can be administered to patients with low platelet counts, acquired or inherited bleeding disorders and acquired or inherited platelet dysfunction. MP can also be administered to prevent or reduce bleeding prior to surgery or in cases of trauma.
|
|
| |
| |
